Importantly, B1SP is capable of inhibiting RTK pathway activation not only by SEMA3C but also by their cognate ligands, EGF and HGF, making this therapeutic protein an attractive multi‐RTK pathway inhibitor targeting MET, ErbB2, and EGFR which are clinically validated targets in a variety of cancers. Here, MET is linked to cancer.